Top Markets
#1 DogBull DogBull +109.06%
#2 MarsCoin MarsCoin +78.17%
#3 Siacoin Siacoin +59.69%
#4 ADO Protocol ADO Protocol +52.87%
#5 The Bitcoin Bull The Bitcoin Bull +26.43%
#6 Ontology Gas Ontology Gas +22.51%
#7 Apertum Apertum +15.00%
#8 Useless Coin Useless Coin +13.73%
#9 Uniswap Uniswap +13.08%
#10 UnifAI Network UnifAI Network +11.99%
Coin of the day
DogBull DogBull
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Hansa Biopharma AB Hansa Biopharma AB

Hansa Biopharma AB

HNSBF
Kedudukan dalam Saham #15161
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development... Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Harga Saham
$3.70
Disegerakkan terakhir: 2026-08-28
Modal Pasaran
$369.01M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
35.04%
Negara
SE
Perdagangan Hansa Biopharma AB (HNSBF)

Kategori

Healthcare
Nisbah P/E bagi Hansa Biopharma AB (HNSBF)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Hansa Biopharma AB, nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Hansa Biopharma AB dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 25.48 -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 217.98 -
US
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.